

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VEPPANU safely and effectively. See full prescribing information for VEPPANU.

VEPPANU (vepedgestrant) tablets, for oral use

Initial U.S. Approval: 2026

INDICATIONS AND USAGE

VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, *estrogen receptor-1 (ESR1)*-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. (1)

DOSAGE AND ADMINISTRATION

- Select patients for treatment with VEPPANU based on the presence of *ESR1* mutation. (2.1)
- Recommended Dosage: 200 mg orally once daily with food. (2.2)
- Interruption, dose reduction, or permanent discontinuation may be required due to adverse reactions. (2.3)

DOSAGE FORMS AND STRENGTHS

Tablets: 100 mg and 200 mg (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

- **QTc Interval Prolongation:** Monitor electrocardiograms (ECGs) and electrolytes prior to initiation of treatment with VEPPANU. Correct hypokalemia and hypomagnesemia prior to and during treatment. Repeat ECGs as clinically indicated. Withhold, reduce dose, or permanently discontinue VEPPANU based on severity. (5.1)
- **Embryo-Fetal Toxicity:** VEPPANU can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (5.2, 8.1, 8.3)

ADVERSE REACTIONS

Most common ($\geq 10\%$) adverse reactions with VEPPANU, including laboratory abnormalities, were decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased platelets, and constipation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-877-702-7846 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- **Strong CYP3A Inhibitors:** Avoid concomitant use with strong CYP3A inhibitors. If concomitant use cannot be avoided, reduce VEPPANU dosage. (2.4, 7.1)
- **Strong CYP3A Inducers:** Avoid concomitant use with strong CYP3A inducers. If concomitant use cannot be avoided, increase VEPPANU dosage. (2.4, 7.1)
- **Certain P-gp Substrates:** Avoid concomitant use with certain P-gp substrates where minimal increases in concentration may lead to serious adverse reactions. (7.2)
- **Certain UGT1A9 Substrates:** Refer to the Prescribing Information for UGT1A9 substrates where minimal increases in concentration may lead to serious adverse reactions. (7.2)

USE IN SPECIFIC POPULATIONS

Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Issued: 05/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Patient Selection
- 2.2 Recommended Dosage and Administration
- 2.3 Dosage Modifications for Adverse Reactions
- 2.4 Dosage Modifications for Drug Interactions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 QTc Interval Prolongation
- 5.2 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience

7 DRUG INTERACTIONS

- 7.1 Effect of Other Drugs on VEPPANU
- 7.2 Effect of VEPPANU on Other Drugs
- 7.3 Drugs that Prolong QTc Interval

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, *estrogen receptor-1 (ESR1)*-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection

Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with VEPPANU based on the presence of *ESR1* mutation(s) in plasma specimen using an FDA-authorized test [*see Indications and Usage (1) and Clinical Studies (14)*].

Information on FDA-authorized tests for detection of *ESR1* mutations in breast cancer is available at: <http://www.fda.gov/CompanionDiagnostics>.

2.2 Recommended Dosage and Administration

The recommended dosage of VEPPANU is 200 mg taken orally once daily with food [*see Clinical Pharmacology (12.3)*] until disease progression or unacceptable toxicity.

Swallow VEPPANU tablet(s) whole. Do not chew, crush, dissolve, or split prior to swallowing. Do not take VEPPANU tablets that are broken, cracked, or look damaged.

If a patient misses a dose or vomits after taking a dose, the patient should take the next dose at the regularly scheduled time.

2.3 Dosage Modifications for Adverse Reactions

The recommended dose reduction for adverse reactions is 100 mg orally once daily.

Permanently discontinue VEPPANU in patients who are unable to tolerate 100 mg orally once daily.

The recommended dosage modifications for VEPPANU for adverse reactions are provided in Table 1 and Table 2.

Table 1: Dosage Modifications for Adverse Reactions (Except QTc Prolongation)

CTCAE Severity Grade	Dosage Modification
Grade 1	No dose modification is required.
Grade 2	Consider interruption of VEPPANU until recovery to Grade ≤ 1 or baseline. Then resume VEPPANU at the same dose.
Grade 3	First occurrence: Interrupt VEPPANU until recovery to Grade ≤ 1 or baseline. Then resume VEPPANU at the same dose or at the reduced dose at the discretion of the physician. If the Grade 3 toxicity recurs, interrupt VEPPANU until recovery to Grade ≤ 1 or baseline. Then resume VEPPANU at the reduced dose or discontinue VEPPANU at the discretion of the physician.
Grade 4	First occurrence: Interrupt VEPPANU until recovery to Grade ≤ 1 or baseline. Then resume VEPPANU at the reduced dose. If a Grade 4 or intolerable adverse reaction recurs, permanently discontinue VEPPANU.

Abbreviations: CTCAE=National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events

Table 2: Dosage Modification and Management for QTc Prolongation

QTc Prolongation ¹ <i>[see Warnings and Precautions (5.1)]</i>	Dosage Modification and Management
QTc >480 ms or >60 ms increase from baseline (and QTc ≤ 500 ms)	Withhold until QTc resolves to ≤ 480 ms and ≤ 60 ms above baseline, then resume VEPPANU at the same dose. Identify and treat reversible causes (e.g., hypokalemia and hypomagnesemia). Initiate more frequent ECG monitoring.
QTc >500 ms	Withhold until QTc resolves to ≤ 480 ms and ≤ 60 ms above baseline, then: <ul style="list-style-type: none"> • resume VEPPANU at the same dose if reversible cause is identified and corrected (e.g., hypokalemia and hypomagnesemia). • resume VEPPANU at the reduced dose if no reversible cause is identified. Initiate more frequent ECG monitoring. Permanently discontinue if QTc >500 ms recurs.
Torsade de Pointes, polymorphic ventricular tachycardia, or signs/symptoms of serious arrhythmia	Permanently discontinue VEPPANU.

¹Heart-rate corrected QTc using Fridericia's method.

2.4 Dosage Modifications for Drug Interactions

Strong CYP3A Inhibitors

Avoid concomitant use with strong CYP3A inhibitors in patients receiving VEPPANU 200 mg once daily. If concomitant use cannot be avoided, reduce VEPPANU from 200 mg once daily to 100 mg once daily [see *Drug Interactions (7.1)*]. After a CYP3A inhibitor has been discontinued for 3 to 5 elimination half-lives, resume VEPPANU 200 mg once daily.

Avoid concomitant use with strong CYP3A inhibitors in patients receiving VEPPANU 100 mg once daily.

Strong CYP3A Inducers

Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 200 mg once daily. If concomitant use cannot be avoided, increase VEPPANU from 200 mg once daily to 300 mg once daily [see *Drug Interactions (7.1)*]. After a CYP3A inducer has been discontinued for 7 to 14 days, resume VEPPANU 200 mg once daily.

Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 100 mg once daily.

3 DOSAGE FORMS AND STRENGTHS

Tablets:

- 100 mg blue film-coated, immediate release, round tablet debossed with “VEP” on one side and “100” on the other side.
- 200 mg blue film-coated, immediate release, oval tablet debossed with “VEP” on one side and “200” on the other side.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 QTc Interval Prolongation

VEPPANU can cause QT (QTc) interval prolongation [see *Clinical Pharmacology (12.2)*].

In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients. The heart-rate corrected QTc interval using Fridericia’s method was greater than 500 msec in 1.6% of patients, and the increase from baseline QTc was greater than 60 msec in 2.6% of patients. VEPPANU dose reduction was required for 0.3% of patients due to QTc interval prolongation [see *Adverse Reactions (6.1)*].

Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to and during treatment with VEPPANU. Perform an ECG prior to initiation of treatment with VEPPANU, and do not initiate VEPPANU in patients with QTc >470 msec. Repeat ECG approximately 4 weeks after initiating treatment and as clinically indicated. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, additional ECG monitoring may be necessary. Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. Reduce VEPPANU dose when concomitant use with strong CYP3A inhibitors cannot be avoided [see *Dosage and Administration (2.4)*, *Drug Interactions (7.1, 7.3)*, and *Clinical Pharmacology (12.2)*]. If concomitant use with other QTc-prolonging agents cannot be avoided, increase the frequency of ECG monitoring.

Withhold, reduce dose, or permanently discontinue based on severity [see *Dosage and Administration (2.3)*].

5.2 Embryo-Fetal Toxicity

Based on findings from animal studies and its mechanism of action, VEPPANU can cause fetal harm when administered to a pregnant woman. In an animal reproduction study, oral administration of vepdegestrant to pregnant rats during the period of organogenesis resulted in adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities, at maternal exposures below the recommended dose based on area under the curve (AUC).

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose [see *Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)*].

6 ADVERSE REACTIONS

The following clinically significant adverse reaction is described elsewhere in the labeling:

- QTc Interval Prolongation [see *Warnings and Precautions (5.1)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of VEPPANU was evaluated in patients with ER-positive, HER2-negative, advanced or metastatic breast cancer following endocrine therapy in VERITAC-2 [see *Clinical Studies (14)*].

Patients received VEPPANU 200 mg orally once daily (N=312) or fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle (N=307). Among patients who received VEPPANU, 33% were exposed for 6 months or longer and 6% were exposed for greater than one year.

Serious adverse reactions occurred in 9% of patients who received VEPPANU. The serious adverse reactions included any fracture (1.3%), fall, hypercalcemia, hepatic injury, pneumonia, musculoskeletal pain (0.6% each), and QTc prolonged (0.3%). Fatal adverse reactions occurred in 1.0% of patients who received VEPPANU, including dyspnea, cerebral ischemia, and unknown cause (one patient each).

Permanent discontinuation of VEPPANU due to an adverse reaction occurred in 2.9% of patients. Adverse reactions that resulted in permanent discontinuation of VEPPANU included increased alanine aminotransferase (ALT) and dyspnea (0.6% each).

Dosage interruptions of VEPPANU due to an adverse reaction occurred in 14% of patients. Adverse reactions which required dosage interruption in >1% of patients included neutropenia (1.9%), anemia, hepatic injury, nausea, fatigue, and musculoskeletal pain (1.3% each).

Dosage reductions of VEPPANU due to an adverse reaction occurred in 1.9% of patients. Adverse reactions which required dosage reductions of VEPPANU included electrocardiogram QT prolonged, fatigue and musculoskeletal pain (0.3% each).

The most common ($\geq 10\%$) adverse reactions, including laboratory abnormalities, were decreased white blood cells, increased AST, musculoskeletal pain, fatigue, decreased hemoglobin, decreased neutrophils, increased ALT, increased alkaline phosphatase, nausea, decreased blood potassium, increased bilirubin, decreased appetite, electrocardiogram QT prolonged, decreased platelets, and constipation.

Table 3 and Table 4 summarize adverse reactions and laboratory abnormalities in VERITAC-2, respectively.

Table 3: Adverse Reactions (≥10%) in Patients with ER+, HER2-, Advanced or Metastatic Breast Cancer Who Received VEPPANU in VERITAC-2^a

Adverse Reaction	VEPPANU N=312		Fulvestrant N=307	
	All Grades %	Grade 3 ^b %	All Grades %	Grade 3 ^b %
Musculoskeletal and Connective Tissue Disorders				
Musculoskeletal pain ^c	30	2.6	23	1
General Disorders and Administration Site Conditions				
Fatigue ^c	29	1	16	1.3
Gastrointestinal Disorders				
Nausea	14	0	9	1
Constipation	10	0	3.3	0
Metabolism and Nutrition Disorders				
Decreased appetite	11	0.3	5	0
Investigations				
Electrocardiogram QT prolonged	10	1.6	1.3	0.3

^a Adverse reactions were graded using NCI CTCAE version 5.0.

^b No Grade 4 events were reported.

^c Includes multiple related terms.

Clinically relevant adverse reactions in <10% of patients who received VEPPANU included headache, hot flush, diarrhea, vomiting, bradycardia, and urinary tract infection.

Table 4: Select Laboratory Abnormalities (≥10%) that Worsened from Baseline in Patients with ER+, HER2-, Advanced or Metastatic Breast Cancer Who Received VEPPANU in VERITAC-2

Laboratory Abnormality	VEPPANU ^a		Fulvestrant ^b	
	All Grades %	Grade 3 or 4 %	All Grades %	Grade 3 or 4 %
Hematology				
White blood cells decreased	33	0.3	15	0.7
Hemoglobin decreased	24	2.3	20	3.6
Neutrophils decreased	23	2.3	13	0.7
Platelets decreased	10	1.3	11	1.3
Chemistry				
Aspartate aminotransferase increased	31	1.6	23	1.7
Alanine aminotransferase increased	22	0.6	23	1.0
Alkaline phosphatase increased	21	0	23	0.3
Blood potassium decreased	14	2.6	6	0.3
Bilirubin increased	14	1.0	8	1.3

^a The denominator used to calculate the rate varied between 308 and 310 based on the number of patients with a baseline value and at least one post-treatment value.

^b The denominator used to calculate the rate varied between 302 and 303 based on the number of patients with a baseline value and at least one post-treatment value.

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on VEPPANU

Table 5 describes drug interactions where concomitant use of another drug affects VEPPANU.

Table 5: Drug Interactions that Affect VEPPANU

Strong CYP3A Inhibitors	
Prevention or Management	<p>Strong CYP3A Inhibitors:</p> <ul style="list-style-type: none">• Avoid concomitant use of VEPPANU with strong CYP3A inhibitors in patients receiving VEPPANU 200 mg once daily. If concomitant use cannot be avoided, reduce VEPPANU dosage [see <i>Dosage and Administration (2.4)</i>].• Avoid concomitant use with strong CYP3A inhibitors in patients receiving VEPPANU 100 mg once daily.
Mechanism and Clinical Effect(s)	<ul style="list-style-type: none">• Vepdegestrant is a CYP3A substrate.• Concomitant use with a strong CYP3A inhibitor may increase vepdegestrant plasma concentration [see <i>Clinical Pharmacology (12.3)</i>], which may increase the risk of VEPPANU-associated adverse reactions.
Strong CYP3A Inducers	
Prevention or Management	<ul style="list-style-type: none">• Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 200 mg once daily. If concomitant use cannot be avoided, increase VEPPANU dosage [see <i>Dosage and Administration (2.4)</i>].• Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 100 mg once daily.
Mechanism and Clinical Effect(s)	<ul style="list-style-type: none">• Vepdegestrant is a CYP3A substrate.• Concomitant use with a strong CYP3A inducer may decrease vepdegestrant plasma concentration [see <i>Clinical Pharmacology (12.3)</i>], which may reduce the effectiveness of VEPPANU.

7.2 Effect of VEPPANU on Other Drugs

Table 6 describes drug interactions where concomitant use of VEPPANU affects another drug.

Table 6: VEPPANU Drug Interactions that Affect Other Drugs

Certain P-gp Substrates	
Prevention or Management	<ul style="list-style-type: none">• Avoid concomitant use with certain P-gp substrates where minimal increases in concentration may lead to serious adverse reactions.
Mechanism and Clinical Effect(s)	<ul style="list-style-type: none">• Vepdegestrant is a P-gp inhibitor.• Vepdegestrant increases exposure of P-gp substrates [see <i>Clinical Pharmacology (12.3)</i>], which may increase the risk of adverse reactions related to these substrates.
Certain UGT1A9 Substrates	
Prevention or Management	<ul style="list-style-type: none">• Refer to the Prescribing Information for UGT1A9 substrates where minimal increases in the concentration may lead to serious adverse reactions.
Mechanism and Clinical Effect(s)	<ul style="list-style-type: none">• Vepdegestrant is a UGT1A9 inhibitor.• Vepdegestrant increases exposure of UGT1A9 substrates [see <i>Clinical Pharmacology (12.3)</i>], which may increase the risk of adverse reactions related to these substrates.

7.3 Drugs that Prolong QTc Interval

Avoid concomitant use of VEPPANU with other drugs with a known potential to prolong the QTc interval.

If concomitant use cannot be avoided:

- Obtain ECGs when initiating and during concomitant use, and as clinically indicated [*see Warnings and Precautions (5.1)*].
- Withhold VEPPANU if the QTc interval is >480 ms or the change from baseline is >60 ms [*see Dosage and Administration (2.3)*].

Vepdegestrant causes QTc interval prolongation [*see Clinical Pharmacology (12.2)*]. Concomitant use of VEPPANU with other drugs that prolong the QTc interval may result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsade de Pointes, other serious arrhythmias, and sudden death [*see Warnings and Precautions (5.1)*].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on findings in animals and its mechanism of action, VEPPANU can cause fetal harm when administered to a pregnant woman [*see Clinical Pharmacology (12.1)*]. There are no available human data on the use of VEPPANU in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of vepdegestrant to pregnant rats during the period of organogenesis caused adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities at maternal exposures below the recommended dose based on AUC (*see Data*). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In an embryo-fetal development study in pregnant rats, administration of oral doses of vepdegestrant up to 300 mg/kg/day during the period of organogenesis resulted in embryo-fetal mortality (increased resorptions, post-implantation loss and reduced number of live fetuses) at ≥ 30 mg/kg/day (approximately 0.3 times the human AUC at the recommended dose). Additional adverse effects at ≥ 30 mg/kg/day included reduced fetal weight and skeletal abnormalities including delays in skeletal ossification (reduced number of ossification sites, incompletely ossified cervical arches or thoracic centra), skeletal malformations (fusion of sacral centra, hemivertebrae of the sacrum), and/or increased incidence of fetal variations (short cervical ribs, misaligned caudal vertebrae, misshapen cervical arches, and misaligned sacral vertebrae).

8.2 Lactation

Risk Summary

There are no data on the presence of vepdegestrant or its metabolites in human milk, or its effects on milk production or the breastfed child. Because of the potential for serious adverse reactions in the breastfed child, advise lactating women not to breastfeed during treatment with VEPPANU and for 2 weeks after the last dose.

8.3 Females and Males of Reproductive Potential

VEPPANU can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations (8.1)*].

Pregnancy Testing

Verify the pregnancy status in females of reproductive potential prior to initiating VEPPANU treatment.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose.

Males

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose.

Infertility

Based on findings from animal studies, VEPPANU may impair fertility in females and males of reproductive potential. The effects of vepdegestrant on fertility were reversible in female animals [see *Nonclinical Toxicology (13.1)*].

8.4 Pediatric Use


The safety and effectiveness of VEPPANU in pediatric patients have not been established.

8.5 Geriatric Use

Of 313 patients who received VEPPANU in the VERITAC-2 study, 39% were 65 years of age or older and 13% were 75 years of age or older. No overall differences in safety or effectiveness of VEPPANU were observed between patients 65 years of age or older compared to younger patients. There is an insufficient number of patients 75 years of age or older to assess whether there are differences in safety or effectiveness.

11 DESCRIPTION

Vepdegestrant is a heterobifunctional protein degrader. It is a small molecule comprised of an estrogen receptor binding domain joined by a linker to an E3 ligase binding domain. The chemical name of vepdegestrant is 2,6-piperidinedione, 3-[1,3-dihydro-1-oxo-5-[4-[[1-[4-[(1*R*,2*S*)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-2*H*-isoindol-2-yl]-, (3*S*)-. The chemical structure of vepdegestrant is:



Vepdegestrant is white to off-white to pale yellow solid with the molecular formula of $C_{45}H_{49}N_5O_4$ and a molecular weight of 723.90 Daltons. Vepdegestrant solubility is pH dependent. The solubility ranges from freely soluble under gastric pH conditions to slightly soluble under intestinal pH conditions.

VEPPANU is supplied as blue film-coated, immediate release tablets containing either 100 mg or 200 mg vepdegestrant together with: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, vitamin E-polyethylene glycol succinate, and Opadry[®] QX Blue as inactive ingredients. Opadry[®] QX Blue film-coating contains: FD&C Blue No. 2 (indigo carmine) aluminum lake, ferric oxide yellow (yellow iron oxide), ferrousferic oxide (black iron oxide), glyceryl mono and dicaprylocaprate (glycerol monocaprylocaprate), polyvinyl alcohol, polyvinyl alcohol polyethylene glycol graft copolymer [macrogol poly (vinyl alcohol) grafted copolymer], talc, and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Vepdegestrant is a heterobifunctional protein degrader that binds to estrogen receptor (ER) and the E3 ligase cereblon (CRBN). This interaction results in the degradation cascade through CRBN-mediated polyubiquitination and degradation of ER by the proteasome, leading to reduction of ER protein levels in breast cancer cells.

Vepdegestrant induced degradation of wild-type (WT) and mutant ER, inhibited ER-dependent breast cancer cell line proliferation *in vitro* and demonstrated antitumor activity *in vivo* in both WT and mutant *ESR1* breast cancer models.

12.2 Pharmacodynamics

The exposure-response relationship and time-course of pharmacodynamic response of vepdegestrant have not been fully characterized.

Cardiac Electrophysiology

The largest mean increase in QTc interval was 12 ms (upper confidence interval = 15 ms) after administration of vepdegestrant at the recommended dosage of 200 mg once daily in patients with *ESR1* mutation-positive breast cancer.

12.3 Pharmacokinetics

Vepdegestrant pharmacokinetics were observed at steady state in patients with ER+/HER2- breast cancer at the approved recommended dosage of 200 mg once daily and are presented as mean (coefficient of variation (CV%)) unless otherwise specified.

Vepdegestrant maximum concentration (C_{max}) is 926 ng/mL (39%) and the total systemic exposure (AUC) is 17,155 ng•hr/mL (36%). Vepdegestrant AUC and C_{max} increase in an approximately dose proportional manner over the dose range of 100 mg (0.5 times the approved recommended dose) to 500 mg (2.5 times the approved recommended dose). Vepdegestrant accumulation is approximately 1.4-fold for AUC and 1.3-fold for C_{max} . Vepdegestrant steady state is reached in approximately 7 days.

Absorption

Vepdegestrant median (min, max) time to maximum plasma concentration (T_{max}) is approximately 6 (4, 8) hours.

Effect of Food

Vepdegestrant AUC increased 2.9-fold and C_{max} 3.2-fold following administration with a high-fat meal (approximately 800 to 1,000 calories; $\geq 50\%$ fat).

Distribution

Vepdegestrant plasma protein binding is >99%. The apparent (oral) volume of distribution is 764 L (26%) following a single 200 mg dose.

Elimination

Vepdegestrant effective elimination half-life is 19 hours (50%) with an apparent (oral) clearance of 12 L/h (36%).

Metabolism

Vepdegestrant is primarily metabolized through direct sulfation via multiple SULT isoforms and oxidation via CYP3A4 and to a lesser extent by CYP2C8, CYP2C9 and CYP3A5. Unchanged total vepdegestrant represented 92% of total radioactivity in plasma.

Excretion

Following a single oral dose of radiolabeled vepdegestrant 200 mg to healthy subjects, approximately 68% of the dose was recovered in feces (18% unchanged) and 1.5% in urine (<0.02% unchanged).

Specific Populations

No clinically significant differences in the pharmacokinetics of vepdegestrant were observed based on age (26 to 89 years), sex, body weight (37 to 181 kg), race (60% White, 27% Asian, 2.2% Black or African American, and 10% other), CLcr 30 mL/min to 90 mL/min (estimated by Cockcroft Gault equation) or mild hepatic impairment (total bilirubin \leq ULN and AST >ULN or total bilirubin >1 to 1.5 \times ULN and any AST).

The effect of moderate hepatic impairment (total bilirubin >1.5 to 3 \times ULN and any AST), severe hepatic impairment (total bilirubin >3 \times ULN and any AST), CLcr 15 to <30 mL/min, and end-stage renal disease (CLcr <15 mL/min) on the pharmacokinetics of vepdegestrant is unknown.

Drug Interaction Studies

Clinical Studies and Model-Informed Approaches

Strong CYP3A Inhibitors: Vepdegestrant AUC increased 1.7-fold and C_{max} 1.5-fold following concomitant use of itraconazole (strong CYP3A inhibitor) 200 mg once daily.

Strong CYP3A Inducers: Vepdegestrant AUC decreased to 64% and C_{max} to 80% following concomitant use of carbamazepine (strong CYP3A inducer) 200 mg three times daily.

Acid Reducing Agents: Vepdegestrant AUC decreased to 84% and C_{max} to 74% following concomitant use of esomeprazole (proton-pump inhibitor) 40 mg once daily.

CYP3A Substrates: Midazolam (CYP3A substrate) AUC increased 1.7-fold and C_{max} 1.2-fold following concomitant use of VEPPANU 200 mg once daily.

P-gp Substrates: Dabigatran etexilate (P-gp substrate) AUC increased 2-fold and C_{max} 1.9-fold following concomitant use of a single dose of VEPPANU 200 mg.

Breast Cancer Resistance Protein (BCRP) Substrates: Rosuvastatin (BCRP substrate) AUC increased 1.2-fold and C_{max} 1.2-fold following concomitant use of a single dose of VEPPANU 200 mg.

UGT1A9 Substrates: Dapagliflozin (UGT1A9 index substrate) AUC is predicted to increase approximately 2-fold following multiple doses of VEPPANU.

In vitro studies:

CYP450 Enzymes: Vepdegestrant does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19 or CYP2D6 and does not induce CYP1A2, CYP2C8, CYP2C9, or CYP2C19. Vepdegestrant is an inhibitor of CYP2B6.

UDP-Glucuronosyltransferases (UGT): Vepdegestrant does not inhibit UGT1A1, UGT1A4, UGT1A6, UGT2B7, or UGT2B15.

Transporter Systems: Vepdegestrant is not a substrate of P-gp, BCRP, OATP1B1, or OATP1B3.

Vepdegestrant does not inhibit MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, or OCT2.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Vepdegestrant was not carcinogenic in a 6-month carcinogenicity study in rasH2 transgenic mice with daily oral administration of vepdegestrant up to 800 mg/kg/day.

Mutagenesis

Vepdegestrant was not mutagenic in an *in vitro* bacterial reverse mutation assay (Ames) or clastogenic in an *in vitro* human lymphocyte micronucleus assay or an *in vivo* rat micronucleus assay.

Impairment of Fertility

Fertility studies with vepdegestrant in animals have not been conducted. In repeat-dose toxicity studies up to 26 weeks duration in rats and 39 weeks duration in dogs, oral administration of vepdegestrant resulted in adverse female reproductive effects including atrophy of the uterus, oviduct, cervix and vagina and follicular cysts in rats at doses ≥ 30 mg/kg/day (0.3 times the human AUC at the recommended dose) and in dogs at doses ≥ 10 mg/kg/day (0.4 times the human AUC at the recommended dose). Additional findings in the ovary in rats included decreased corpora lutea and follicle hemorrhage at ≥ 30 mg/kg/day. Oral administration of vepdegestrant resulted in adverse male reproductive effects including decreased epididymis and prostate weights with decreased secretion and decreased secretion in the seminal vesicle in rats at doses ≥ 30 mg/kg/day, and seminiferous tubular degeneration, hypoplasia of seminiferous tubules, and epididymal epithelial cell necrosis in dogs at 90 mg/kg/day (approximately 2 times the human AUC at the recommended dose). The effects of vepdegestrant on female reproductive organs were reversible following a 4-week recovery period. The effects on male reproductive organs were not reversible following a 4-week recovery period.

13.2 Animal Toxicology and/or Pharmacology

In a 6-month repeat-dose toxicity study, oral administration of vepdegestrant to rats resulted in granulosa cell hyperplasia in the ovary at 300 mg/kg/day (5 times the human AUC at the recommended dose). In a 9-month repeat-dose toxicity study, oral administration of vepdegestrant to dogs resulted in interstitial cell hypertrophy/hyperplasia in the testis at doses ≥ 10 mg/kg/day (0.4 times the human AUC at the recommended dose). Reversibility was not assessed.

14 CLINICAL STUDIES

The efficacy of VEPPANU was evaluated in VERITAC-2 (NCT05654623), a randomized, open-label, active-controlled, multicenter trial that enrolled 624 adult patients with ER-positive, HER2-negative, advanced or metastatic breast cancer, of whom 270 patients had tumors carrying *ESR1* mutations. Patients were required to have disease progression on 1 to 2 prior lines of endocrine therapy, including 1 line with a CDK4/6 inhibitor. Progression during or within 12 months from the end of adjuvant therapy was counted as 1 line of endocrine therapy for advanced/metastatic setting. Pre-menopausal and peri-menopausal women and men received a gonadotropin-releasing hormone (GnRH) agonist. Patients were excluded if they had received chemotherapy for advanced or metastatic disease or fulvestrant in any line of therapy, or if progression on the most recent line of endocrine therapy occurred within the first 6 months.

Patients were randomized 1:1 to receive VEPPANU 200 mg orally once daily (N=313), or fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and then once monthly thereafter (N=311). Randomization was stratified by *ESR1* mutation status (detected vs. not detected) and visceral metastasis (yes vs. no). *ESR1* mutational status was determined by blood circulating tumor deoxyribonucleic acid (ctDNA) using central or local testing. Patients were treated until disease progression or unacceptable toxicity.

Among the patients whose tumors had *ESR1* mutations (N=270), the median age was 60 (range: 26 to 87) years; all but 1 were female; 47% were White; 41% Asian; 3.3% Black; 8% unknown/not reported; 7% were Hispanic/Latino, 83% were Not Hispanic or Latino and 10% not reported. Of the 269 women, 20% were pre/perimenopausal. Baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 (57%) or 1 (43%). Most patients (68%) had visceral disease; 81% had received 1 line of endocrine therapy and 19% had received 2 lines of endocrine therapy in the advanced or metastatic setting. All patients had received prior treatment with a CDK4/6 inhibitor.

The major efficacy outcome was progression-free survival (PFS) as assessed by blinded independent central review (BICR) in the population of patients whose tumors had an *ESR1* mutation and in the overall population evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Additional efficacy outcomes were overall survival (OS) and objective response rate (ORR) as assessed by BICR.

A statistically significant difference in PFS by BICR was observed for the patients whose tumors had *ESR1* mutations for VEPPANU compared with fulvestrant.

Overall survival was immature with 16% of deaths in this population at the time of the PFS analysis. Efficacy results are provided in Table 7 and Figure 1.

Table 7: Efficacy Results for VERITAC-2 (Patients with *ESR1*-Mutated Tumors)

	VEPPANU N=136	Fulvestrant N=134
Progression-free Survival*		
Number of events (%)	79 (58)	95 (71)
Median in months (95% CI)	5.0 (3.7, 7.4)	2.1 (1.9, 3.5)
Hazard ratio (95% CI) ^a	0.57 (0.42, 0.77)	
p-value (1-sided) ^b	0.0001	
Confirmed Objective Response Rate*		
Patients with measurable disease	97	100
ORR (95% CI)	19% (12, 27)	4% (1.6, 10)
Complete response rate	0%	0%
Partial response rate	19%	4%


Abbreviations: CI=Confidence interval; n=number of events; N=number of participants

* By blinded independent central review (BICR).

^a Hazard ratio based on stratified Cox proportional hazards model.

^b p-value based on stratified log-rank test (compared to a significance level of 0.01875).

Figure 1: Kaplan-Meier Plot of Progression-Free Survival Based on BICR Assessment in VERITAC-2 (Patients with *ESRI*-Mutated Tumors)



No. at risk

VEPPANU:	136	134	87	78	55	53	38	37	22	22	15	14	10	8	4	3	3	2	0
Fulvestrant:	134	125	62	52	30	29	15	12	8	8	7	2	1	1	1	1	0	0	0

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

VEPPANU (vepedegestrant) film-coated tablets for oral use are supplied in bottles of 30 tablets with child-resistant closures as follows:

Strength	Description	NDC Number
100 mg	Blue round tablet “VEP” debossed on one side and “100” on the other side.	84043-100-30
200 mg	Blue oval tablet “VEP” debossed on one side and “200” on the other side.	84043-200-30

Storage

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (between 59°F and 86°F) [see USP controlled room temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

QTc Interval Prolongation

Inform patients that VEPPANU can cause QTc interval prolongation, which may increase the risk of Torsade de Pointes, other ventricular arrhythmias, and sudden death. Advise patients or caregivers of the signs or symptoms associated with the clinical consequences of QTc interval prolongation and to seek immediate medical attention if these are suspected or develop. Instruct patients to consult with their healthcare provider prior to taking other drugs that cause QTc interval prolongation with VEPPANU [see *Warnings and Precautions (5.1) and Drug Interactions (7.3)*].

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions (5.2) and Use in Specific Populations (8.1)*].

Advise females of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose [see *Use in Specific Populations (8.3)*].

Lactation

Advise women not to breastfeed during treatment with VEPPANU and for 2 weeks after the last dose [see *Use in Specific Populations (8.2)*].

Infertility

Advise males and females of reproductive potential that VEPPANU may impair fertility [see *Use in Specific Populations (8.3)*].

Drug Interactions

Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John's wort, grapefruit, or grapefruit juice while taking VEPPANU [see *Drug Interactions (7.1, 7.2)*].

Administration

Advise patients to take VEPPANU with food, how to make up for missed or vomited dose, and to swallow tablet(s) whole without chewing, crushing, dissolving or splitting the tablet [see *Dosage and Administration (2.2)*].

Manufactured by:
Pfizer Inc.
New York, NY 10001

Distributed by:
Arvinas Operations, Inc.
New Haven, CT 06511

PATIENT INFORMATION
VEPPANU (VEP-uh-new)
(vepdegestrant)
tablets, for oral use

What is VEPPANU?

VEPPANU is a prescription medicine to treat people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, *ESR1*-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), **and** whose disease has progressed after at least one line of endocrine-based therapy.

Your healthcare provider will perform a test to make sure that VEPPANU is right for you.

It is not known if VEPPANU is safe and effective in children.

Before taking VEPPANU, tell your healthcare provider about all of your medical conditions, including if you:

- have heart failure or heart rhythm problems, including QTc prolongation, and long QTc syndrome
- have low blood levels of potassium or magnesium
- are pregnant or plan to become pregnant. VEPPANU can harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider may do a pregnancy test before you start treatment with VEPPANU.
- Use effective birth control (contraception) during treatment with VEPPANU and for 2 weeks after the last dose.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VEPPANU.

Males with female partners who are able to become pregnant:

- Use effective birth control (contraception) during treatment with VEPPANU and for 2 weeks after the last dose.
- are breastfeeding or plan to breastfeed. It is not known if VEPPANU passes into your breast milk. Do not breastfeed during treatment with VEPPANU and for 2 weeks after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

VEPPANU and other medicines may affect the way each other works and may cause serious side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take VEPPANU?

- Take VEPPANU exactly as your healthcare provider tells you.
- Do not change your dose or stop taking VEPPANU unless your healthcare provider tells you.
- Take VEPPANU 1 time each day.
- Take VEPPANU with food.
- Swallow VEPPANU tablets whole. Do not chew, crush, dissolve, or split the tablets before swallowing.
- Do not take VEPPANU tablets that are broken, cracked, or look damaged.
- If you miss a dose or vomit after taking VEPPANU, do not take another dose of VEPPANU on that day. Take your next dose the following day at your regularly scheduled time. Do not take 2 doses on the next treatment day.

What should I avoid while taking VEPPANU?

Avoid taking St. John's wort, eating grapefruit, or drinking grapefruit juice during with treatment with VEPPANU.

What are the possible side effects of VEPPANU?

VEPPANU can cause serious side effects, including:

- **Heart rhythm problems (QTc interval prolongation).** VEPPANU can cause changes in the electrical activity of your heart and may increase your risk of abnormal heart rhythm problems, and sudden death. Your healthcare provider will check your heart with a test called an electrocardiogram (ECG) and check your blood potassium and magnesium levels before and as needed during treatment with VEPPANU. Get emergency medical help right away if you get any signs and symptoms of abnormal heart rhythm, including:
 - feeling lightheaded or faint
 - feeling that your heart is pounding
 - shortness of breath
 - dizziness
 - or beating fast (heart palpitations)
 - chest pain

The most common side effects of VEPPANU include:

- decreased white blood cell counts
- increased liver function tests
- muscle and bone pain
- tiredness
- decreased red blood cell counts
- nausea
- decreased potassium levels in your blood
- decreased appetite
- abnormal electrocardiogram (QT prolonged)
- decreased platelet counts
- constipation

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with VEPPANU, if you develop certain side effects.

VEPPANU may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of VEPPANU.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store VEPPANU?

- Store VEPPANU at room temperature between 68°F to 77°F (20°C to 25°C).
- VEPPANU comes in a bottle with a child-resistant closure.

Keep VEPPANU and all medicines out of the reach of children.

General information about the safe and effective use of VEPPANU.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VEPPANU for a condition for which it was not prescribed. Do not give VEPPANU to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VEPPANU that is written for health professionals.

What are the ingredients in VEPPANU?

Active ingredient: vepdegestrant

Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, vitamin E-polyethylene glycol succinate, and Opadry® QX Blue that consists of FD&C Blue No. 2 (indigo carmine) aluminum lake, ferric oxide yellow (yellow iron oxide), ferrousferrous oxide (black iron oxide), glyceryl mono and dicaprylocaprate (glycerol monocaprylocaprate), polyvinyl alcohol, polyvinyl alcohol polyethylene glycol graft copolymer [macrogol poly (vinyl alcohol) grafted copolymer], talc, and titanium dioxide.

Manufactured by: Pfizer Inc. New York, NY 10001

Distributed by: Arvinas Operations, Inc. New Haven, CT 06511

For more information, go to www.VEPPANU.com or call 1-877-702-7846